Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIATM sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2186.45 as compared to the previous close of Rs. 2147.40. The total number of shares traded during the day was 21926 in over 2306 trades.

The stock hit an intraday high of Rs. 2236.15 and intraday low of 2146.65. The net turnover during the day was Rs. 48380802.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 MilnacipranHydrochloride